Immunoprotein Diagnostic Testing Market Analysis by Test Type, by Application, by Technology and by Region - Forecast to 2029

The global immunoprotein diagnostic testing market size is estimated to be USD 10.92 billion in 2021 and is expected to witness a CAGR of 6.81% during the forecast period. Increase in technological development in the market is a key driver for the growth of the global immunoprotein diagnostic testing market. Additionally, growing R&D investments in the immunoprotein diagnostic testing market and considered initiatives by key players to attain a larger market share in the immunoprotein diagnostic testing market are some of the other drivers propelling the market growth. Nevertheless, the stringent regulatory situations in the developed economies and the high cost of immunoprotein diagnostic testing treatment are expected to restrain the global market growth.

By Test Type

Based on test type, the market is segmented into haptoglobin diagnostic tests, immunoglobulin diagnostic tests, free light chain diagnostic tests, C - reactive protein (CRP) diagnostic tests, complement system proteins diagnostic tests, and prealbumin diagnostic tests. In 2021, the immunoglobulin diagnostic tests segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to these tests being commonly used and these tests help healthcare professionals to collect information about the functioning of a patient’s immune system worldwide. C - reactive protein (CRP) diagnostic tests segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the capability of this test for detecting inflammation in a patient’s body by assessing the amount of CRP.

By Application

Based on application, the market is categorized into allergy testing, infectious disease testing, endocrine testing, oncology testing, autoimmune disease testing, and toxicology testing. In 2021, the infectious disease testing segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the rise in the occurrence of various types of chronic infectious diseases, such as HIV/AIDS worldwide. The oncology testing segment is anticipated to grow at a profitable CAGR during the forecast period, due to the launch of new products and the high number of cancer incidences throughout the world.

By Technology

Based on technology, the market is categorized into chemiluminescence assay, enzyme based immunoassay, radioimmunoassay, immunoprotein electrophoresis, immunofluorescence assay, and immunoturbidity assay. In 2021, the enzyme-based immunoassay segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to its usage as a diagnostic tool and a quality control tool in numerous companies and laboratories worldwide. The chemiluminescence assay segment is anticipated to grow at a profitable CAGR during the forecast period, due to the high rate of application of this technology as it offers high sensitivity and specificity coupled with its ability to detect antigens in plasma samples and human serum.

Regional Insights

In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the favourable repayment scenarios, well-known healthcare infrastructure in the U.S., this has led to the rising use of immunoprotein diagnostic instruments in laboratories and diagnostic centres in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the less stringent regulations, tremendously rapid economic development along with rapid development of the medical healthcare system that are the major factors in this region. Competitor Insights Some of the key players in the immunoprotein diagnostic testing market are Abbott Laboratories (U.S.); Abcam Plc (U.K.); Bio-Rad Laboratories, Inc. (U.S.); Beckman Coulter, Inc. (U.S.); Diasorin S.P.A (Italy); Enzo Biochem, Inc. (U.S.); Hoffmann-La Roche Ag (Switzerland); Ortho Clinical Diagnostics (U.S.); Siemens Healthcare GmbH (Germany); and Thermo Fisher Scientific, Inc. (U.S.). The leading players operating in the immunoprotein diagnostic testing industry are adopting various strategies including R&D investments, adoption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share. This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The immunoprotein diagnostic testing market report is categorized into the following segments and subsegments:

Immunoprotein Diagnostic Testing Market, By Test Type (Revenue, USD Billion, 2021 - 2029)

• Haptoglobin Diagnostic Tests
• Immunoglobulin Diagnostic Tests
• Free Light Chain Diagnostic Tests
• C-Reactive Protein (CRP) Diagnostic Tests
• Complement System Proteins Diagnostic Tests
• Prealbumin Diagnostic Tests

Immunoprotein Diagnostic Testing Market, By Application (Revenue, USD Billion, 2021 - 2029)

• Allergy Testing
• Infectious Disease Testing
• Endocrine Testing
• Oncology Testing
• Autoimmune Disease Testing
• Toxicology Testing

Immunoprotein Diagnostic Testing Market, By Technology (Revenue, USD Billion, 2021 - 2029)

• Chemiluminescence Assay
• Enzyme Based Immunoassay
• Radioimmunoassay
• Immunoprotein Electrophoresis
• Immunofluorescence Assay
• Immunoturbidity Assay

Immunoprotein Diagnostic Testing Market, By Region (Revenue, USD Billion, 2021 - 2029)

North America

• U.S.
• Canada

Europe

• Germany
• France
• UK
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC

Latin America

• Brazil
• Mexico
• Argentina
• Rest of LATAM

Middle East & Africa

• South Africa
• Saudi Arabia
• Rest of MEA